Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E22.78 EPS (ttm)5.91 Insider Own0.02% Shs Outstand2.69B Perf Week0.99%
Market Cap362.65B Forward P/E17.42 EPS next Y7.73 Insider Trans-35.45% Shs Float2.67B Perf Month1.27%
Income16.34B PEG3.59 EPS next Q1.79 Inst Own67.60% Short Float0.52% Perf Quarter5.63%
Sales72.53B P/S5.00 EPS this Y8.30% Inst Trans-0.27% Short Ratio2.49 Perf Half Y12.70%
Book/sh26.72 P/B5.04 EPS next Y7.69% ROA11.30% Target Price136.89 Perf Year13.07%
Cash/sh4.77 P/C28.22 EPS next 5Y6.35% ROE22.90% 52W Range109.32 - 137.08 Perf YTD16.92%
Dividend3.36 P/FCF41.06 EPS past 5Y11.20% ROI17.00% 52W High-2.94% Beta0.78
Dividend %2.49% Quick Ratio1.00 Sales past 5Y2.00% Gross Margin69.40% 52W Low21.71% ATR1.55
Employees126400 Current Ratio1.30 Sales Q/Q1.90% Oper. Margin27.50% RSI (14)47.29 Volatility1.14% 1.08%
OptionableYes Debt/Eq0.48 EPS Q/Q-2.40% Profit Margin22.50% Rel Volume0.66 Prev Close134.70
ShortableYes LT Debt/Eq0.38 EarningsJul 18 BMO Payout53.80% Avg Volume5.53M Price133.05
Recom2.60 SMA200.16% SMA50-0.18% SMA2007.69% Volume3,271,129 Change-1.22%
Jul-21-17Downgrade BTIG Research Neutral → Sell $110
Jul-21-17Downgrade Alembic Global Advisors Neutral → Underweight
Jul-20-17Resumed Credit Suisse Outperform $148
Jul-05-17Reiterated Morgan Stanley Overweight $135 → $140
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Aug-23-17 12:02PM  Markets Right Now: Stocks slip in midday trading Associated Press
08:04AM  How Johnson & Johnson Makes Most of Its Money Motley Fool
07:10AM  Massive California verdict expands J&J's talc battlefield Reuters
Aug-22-17 11:19PM  AP Top Extended Financial Headlines at 11:19 p.m. EDT Associated Press
05:54PM  Massive California verdict expands J&J's talc battlefield Reuters
02:34PM  J&J steps into death penalty debate CNBC Videos
02:20PM  Johnson & Johnson to Pay $407 Million In Trial Linking Talc Use to Ovarian Cancer Fortune Videos
01:37PM  Does Johnson & Johnson Baby Powder Cause Ovarian Cancer? Heres What We Know Fortune
08:40AM  Jury Awards Woman $417 Million On Allegation Johnson & Johnson Talcum Powder Gave Her Cancer Benzinga
08:26AM  J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection
08:24AM  Johnson & Johnson breached its 50 day moving average in a Bullish Manner : JNJ-US : August 22, 2017 Capital Cube
07:44AM  President Trump Outlines Plans for Fighting in Afghanistan Videos
07:33AM  3 Top Stocks Under $5 Motley Fool
07:23AM  3 Most Promising Cancer Drugs in Late-Stage Development Motley Fool
01:17AM  PRESS DIGEST-New York Times business news - Aug 22 Reuters
12:08AM  [$$] Johnson & Johnson Hit With $417 Million Verdict in Baby Powder Case The Wall Street Journal
12:08AM  [$$] Johnson & Johnson Wades Into Death Penalty Debate For First Time The Wall Street Journal
Aug-21-17 10:47PM  Record $417M award in lawsuit linking baby powder to cancer Associated Press
07:41PM  Johnson & Johnson to pay $417 million in latest cancer lawsuit
04:13PM  The Latest: Plaintiff wanted to help others in talc case Associated Press
03:39PM  J&J ordered to pay $417 million in trial over talc cancer risks Reuters
03:37PM  J&J ordered to pay $417 mln in trial over talc cancer risks Reuters
03:12PM  [$$] Johnson & Johnson Hit With $417 Million Verdict in Baby Powder Case The Wall Street Journal
02:27PM  [$$] Johnson & Johnson unit speaks out at planned death row drug use Financial Times
02:21PM  J&J ordered to pay $417 million in trial over talc cancer risks Reuters
01:51PM  J&J Slammed With $417 Million Verdict in California Talc Cancer Trial
01:47PM  J&J Loses $417 Million Talc Verdict in First California Case Bloomberg
Aug-19-17 03:21PM  3 Top Biotech Stocks Under $5 Motley Fool
Aug-18-17 08:39PM  3 Healthcare Stocks I'll Hold Forever Motley Fool
05:33PM  Bayer, J&J win third U.S. trial over Xarelto bleeding risk Reuters
11:20AM  The Biggest Thing Big Business Can Teach Non-Profits Fortune
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
07:39AM  Analysts Recommendations for Bristol-Myers Squibb in August 2017 Market Realist
Aug-17-17 02:00PM  Remicade Is a Litmus Test for PBMs Bloomberg
10:31AM  How Safe Is Johnson & Johnson's Dividend? Motley Fool
08:01AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
06:23AM  In Trump CEO Council Exodus, Early Movers Stand Out
Aug-16-17 02:24PM  J&J's First California Talc-Powder Trial Is Headed to the Jury Bloomberg
01:57PM  7 members of Trump's manufacturing council left after Charlottesville before Trump disbanded it Business Insider
01:33PM  Jamie Dimon on Trump: 'It is a leader's role ... to bring people together, not tear them apart' CNBC
01:22PM  What Shareholders Should Make of the Johnson & Johnson-Cerecor Situation
01:15PM  As Trump disbanded advisory groups, this is who was in and who was out CNBC
11:55AM  India introduces price controls for knee implants Reuters
10:16AM  The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak InvestorPlace
09:06AM  India introduces price controls for knee implants Reuters
08:21AM  [$$] Donald Trump attacks CEO 'grandstanders' as more quit panel Financial Times
Aug-15-17 07:39PM  Business leaders quit Trump panel; he hits back hard Associated Press
07:02PM  Will Any Major CEOs Join Trumps Shrinking Jobs Councils After His Latest Charlottesville Comments? Fortune
05:41PM  Trump loudly insists both sides to blame for Virginia violence Reuters
04:16PM  Yacktman Fund 2nd Quarter Commentary
03:57PM  Johnson & Johnson CEO to stay on Trump's advisory council to advocate for health care CNBC
01:33PM  South Carolina sues drug manufacturer over opioid crisis Associated Press
10:41AM  Lawsuit accuses drug manufacturer of worsening opioid crisis Associated Press
10:06AM  Catalyst (CPRX) Focused on Development of Pipeline Candidates Zacks
09:00AM  Amazon: The Devil You Know and the Devil You Dont 24/7 Wall St.
05:00AM  Whats Harder Than Making Copycat Biotech Drugs? Selling Them Bloomberg
Aug-14-17 07:48PM  3 Dividend Stocks Ideal for Retirees Motley Fool
07:07PM  Mercks CEO Isnt the First Biopharma Chief to Tangle With Trump Over Race Fortune
10:37AM  Pfizers Major Growth Drivers in 2Q17 Market Realist
10:37AM  Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern Zacks
09:47AM  Johnson & Johnson to Participate in 2017 Morgan Stanley Global Health Care Conference PR Newswire
09:20AM  Pacira Pharmaceuticals Focuses on Exparel's Label Expansion Zacks
Aug-13-17 02:03PM  Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions? Motley Fool
07:23AM  5 Dividend Stocks That Pay Out Over $8 Billion a Year Motley Fool
Aug-12-17 10:40AM  Edited Transcript of JNJ earnings conference call or presentation 18-Jul-17 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Aug-11-17 03:59PM  Pfizers Valuation after 2Q17 Earnings Market Realist
01:01PM  3 Billionaire Stocks for Retirees Motley Fool
10:27AM  More than half of women who got an abortion last year were using contraception MarketWatch
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Aug-10-17 01:38PM  BUZZ- DJI: From hot to not Reuters
11:06AM  Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence
10:10AM  Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up Zacks
09:07AM  Celgenes Otezla Witnessed High Revenue Growth in 2Q17 Market Realist
07:37AM  How Celgenes Pomalyst Is Positioned after 2Q17 Market Realist
Aug-09-17 01:06PM  2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July Motley Fool
12:57PM  Why Achillion Pharmaceuticals Is Shooting 25% Higher Today Motley Fool
10:51AM  Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update Zacks
09:25AM  Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : August 9, 2017 Capital Cube
08:20AM  The 3 Best Buffett Stocks for Retirees Motley Fool
07:40AM  Has Johnson & Johnson Been Able to Increase Dividends? Market Realist
Aug-08-17 09:00PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher InvestorPlace
05:56PM  Johnson & Johnson Value Analysis (NYSE:JNJ) : August 8, 2017 Capital Cube
01:59PM  As Drug Overdoses Hit Record High, Trump Offers Little on Opioid Policy Fortune
12:37PM  Why Martin Shkreli Wont Be the Last Pharma Bro Fortune
Aug-07-17 06:10PM  Endo Sets Aside $775 Million to Settle Remaining Mesh Lawsuits Bloomberg
05:04PM  What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool
02:27PM  Why Minerva Neurosciences Inc. Fell 31.1% in July Motley Fool
09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
08:07AM  Beneath the glow of stock-market records, darkly bearish trends are lurking MarketWatch
07:38AM  Imbruvica Could Significantly Drive AbbVies Revenue Growth Market Realist
Aug-06-17 10:37AM  AbbVies new, cheaper hepatitis C drug could launch the drug worlds own Hunger Games MarketWatch
Aug-04-17 05:17PM  Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years Motley Fool
03:35PM  Whats Next for the Healthcare Sector after a Weak July? Market Realist
02:28PM  Johnson & Johnson to Participate in the 2017 Wells Fargo 12th Annual Healthcare Conference PR Newswire
02:17PM  Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference PR Newswire
11:13AM  [$$] CVS Formulary Changes Boost JNJ, Pfizer; Hurt Lilly
10:39AM  Analysts Recommendations for AbbVie in August 2017 Market Realist
08:47AM  Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals Zacks
Aug-03-17 02:41PM  How Avons CEO Failed to Fix the Company Fortune
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusExec VP, Chief Scientific OffJul 24Option Exercise72.54102,6927,449,278230,342Jul 26 11:49 AM
Stoffels PaulusExec VP, Chief Scientific OffJul 24Sale133.14102,69213,672,629127,650Jul 26 11:49 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Option Exercise61.7582,5915,099,994226,693Jul 24 11:06 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Sale136.7282,59111,291,478144,102Jul 24 11:06 AM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM